AnlongBio Secures ~$14M in B+ Round, Inks over $100M Global Strategic Partnership

AnlongBio recently announced the completion of a B+ round of financing amounting to nearly 100 million RMB (~$14 million U.S. dollars). This round was led by the Beijing Medical and Health Industry Investment Fund and the Beijing Shunyi Airport Industrial Fund, representing investments from both municipal and district-level capital sources. Simultaneously, AnlongBio has entered into an international strategic cooperation agreement with a Nasdaq-listed U.S. company in the field of small nucleic acid drugs. The collaboration is valued at over 100 million U.S. dollars, marking a significant breakthrough for AnlongBio in international licensing deals.

In terms of product development progress, AnlongBio has continued to advance multiple product pipelines. The gene therapy product for wet age-related macular degeneration (wAMD) via suprachoroidal delivery has completed Phase II clinical enrollment and has received approval from the Center for Drug Evaluation (CDE) to conduct Phase II clinical trials for diabetic retinopathy. This milestone demonstrates AnlongBio's mature R&D capability in parallel development across multiple indications. In the field of small nucleic acid innovative drug development, the hepatitis B (HBV) project in collaboration with Kawin Technology has entered the clinical stage, while a product developed in partnership with Sunshine Nohe has also initiated clinical application. To date, AnlongBio has established collaborations with five listed companies in China and internationally, earning broad recognition from capital investors and partners for its technological strength and industrial potential.

Since 2021, the gene therapy field has faced successive challenges. Following several severe clinical incidents involving AAV vectors globally, the application of this technology has remained largely confined to rare diseases. Multinational pharmaceutical companies have adjusted their strategic layouts accordingly, industry investments have entered a downturn, and domestic companies in China have encountered extreme difficulties in financing. The clinical incident involving Adverum in the United States has further cast significant uncertainty over the application prospects of AAV in chronic disease areas such as wet age-related macular degeneration and diabetic retinopathy. Against this backdrop, AnlongBio's adoption of the suprachoroidal delivery route ensures efficacy while significantly reducing inflammatory risks, providing a critical solution for the application of AAV technology in this field. Gene therapy subsidiaries of Kanghong Pharmaceutical and Hengrui Pharma have successively adopted this approach, fully validating the scientific value and application potential of this technological pathway.

With a long-term strategic vision, AnlongBio aspires to become a leading enterprise in China's gene therapy and nucleic acid drug sector. Through years of dedicated investment, the company has achieved strategic expansion across two major technology platforms: gene therapy and small nucleic acid drugs.

Collaborations with multiple listed companies in China have not only honed the R&D and clinical teams but also validated AnlongBio's technological strength in liver-targeted delivery systems. Meanwhile, partnerships with overseas companies have further demonstrated its capabilities in extrahepatic targeted delivery, providing strong support for its proprietary products to enter international markets such as Europe and the United States. While expanding globally, AnlongBio retains its commercial rights in the Greater China region, ensuring the ability to continue delivering high-value innovative therapies to Chinese patients.

Currently, China's biopharmaceutical industry, after a period of fluctuation, is embracing recovery opportunities through licensing deals with multinational pharmaceutical companies in Europe and the United States. However, to truly evolve into globally competitive biopharmaceutical enterprises, Chinese companies must not only possess cross-platform R&D capabilities and the ability to consistently develop breakthrough products but also deepen their presence in the Chinese market and master the commercialization of proprietary products. AnlongBio's transition from gene therapy to nucleic acid drugs, despite its challenges, fully demonstrates its cross-platform R&D prowess. Its collaborations with international partners further reflect a deep understanding of both in China and global pharmaceutical markets, as well as its potential for commercialization.